BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
暂无分享,去创建一个
D. Merico | M. Shago | N. Alon | K. Ligon | J. Rutka | C. Hawkins | A. Shlien | P. Ray | M. Remke | P. Dirks | Michael D. Taylor | A. Huang | D. Malkin | J. Chan | V. Ramaswamy | U. Tabori | E. Bouffet | Cindy H. Zhang | M. Greenberg | P. Castelo-Branco | S. Laughlin | J. Pole | P. Buczkowicz | Joshua Mangerel | P. Rakopoulos | A. G. Guerreiro Stucklin | N. Zhukova | R. Krishnatry | M. Mistry | E. Young | J. Stavropoulos | D. Bakry | Vilma Navickiene | Martin Li
[1] C. Hawkins,et al. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications , 2014, Acta Neuropathologica.
[2] M. Antunes,et al. When what appears to be mitral stenosis is not: diagnostic and therapeutic implications. , 2014, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.
[3] Chris Sander,et al. Erratum: The somatic genomic landscape of glioblastoma (Cell (2013) 155 (462-477)) , 2014 .
[4] Ming-Nan Chien,et al. Significance of Allelic Percentage of BRAF c.1799T > A (V600E) Mutation in Papillary Thyroid Carcinoma , 2014, Annals of Surgical Oncology.
[5] Amar Gajjar,et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.
[6] Michael Brudno,et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations , 2014, Nature Genetics.
[7] C. Hawkins,et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. , 2014, European journal of cancer.
[8] Steven J. M. Jones,et al. Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.
[9] Scott L. Pomeroy,et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma , 2013, Acta Neuropathologica.
[10] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[11] Mark L. Greenberg,et al. Late mortality after hematopoietic SCT for a childhood malignancy , 2013, Bone Marrow Transplantation.
[12] J. Pole,et al. Early deaths in pediatric acute leukemia: a population-based study , 2013, Leukemia & lymphoma.
[13] Roland Eils,et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.
[14] D. Gutmann,et al. BRAFV600E mutation is a negative prognosticator in pediatric ganglioglioma , 2013, Acta Neuropathologica.
[15] Heather L. Mulder,et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.
[16] Gary L. Gallia,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.
[17] M. Preusser,et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells , 2013, Acta Neuropathologica.
[18] Lynda Chin,et al. Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2013, Science.
[19] David T. W. Jones,et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas , 2013, Acta Neuropathologica.
[20] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[21] N. Foreman,et al. Brainstem ganglioglioma successfully treated with vemurafenib. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[23] David T. W. Jones,et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.
[24] Timothy A. Chan,et al. Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma , 2012, Oncotarget.
[25] R. Barbella-Aponte,et al. Xantoastrocitoma pleomórfico con extensión intraventricular y transformación anaplásica en paciente adulto: caso clínico , 2012 .
[26] Amy Y. M. Au,et al. Detection of alternative lengthening of telomeres by telomere quantitative PCR , 2012, Nucleic acids research.
[27] David T. W. Jones,et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.
[28] C. Hawkins,et al. Favorable outcome with conservative treatment for children with low grade brainstem tumors , 2012, Pediatric blood & cancer.
[29] D. Malkin,et al. Syndromes Predisposing to Pediatric Central Nervous System Tumors: Lessons Learned and New Promises , 2012, Current Neurology and Neuroscience Reports.
[30] F. Binesh,et al. Pleomorphic xanthoastrocytoma with malignant transformation and multiple recurrences in an Iranian girl , 2012, BMJ Case Reports.
[31] P. Varlet,et al. Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas , 2012, PloS one.
[32] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[33] Li Ding,et al. Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.
[34] T. Merchant,et al. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Barbara S. Paugh,et al. Targeted Therapy for BRAFV600E Malignant Astrocytoma , 2011, Clinical Cancer Research.
[36] Barbara S. Paugh,et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[38] N. Alon,et al. BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma , 2011, Clinical Cancer Research.
[39] A. Iafrate,et al. BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications , 2011, PloS one.
[40] J. O’Leary,et al. BRAFV600E: Implications for Carcinogenesis and Molecular Therapy , 2011, Molecular Cancer Therapeutics.
[41] T. Merchant,et al. Survival and long-term health and cognitive outcomes after low-grade glioma. , 2011, Neuro-oncology.
[42] J. Lowe,et al. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. , 2011, Neuro-oncology.
[43] Kirsten Schmieder,et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.
[44] T. Cloughesy,et al. New Strategies in the Molecular Targeting of Glioblastoma: How Do You Hit a Moving Target? , 2011, Clinical Cancer Research.
[45] L. Goumnerova,et al. Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1 , 2010, Pediatric blood & cancer.
[46] A. Ashworth,et al. A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas , 2010, Clinical Cancer Research.
[47] Richard G Grundy,et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] C. Hawkins,et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] F. Giangaspero,et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas , 2010, Journal of Neuro-Oncology.
[50] A. Montpetit,et al. Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. , 2010, Neuro-oncology.
[51] Hanlee P. Ji,et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. , 2010, Cancer research.
[52] A. Gajjar,et al. Outcome and prognostic features in pediatric gliomas , 2009, Cancer.
[53] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[54] Amy Y. M. Au,et al. DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity , 2009, Nature Biotechnology.
[55] T. Forshew,et al. MAPK pathway activation and the origins of pediatric low‐grade astrocytomas , 2009, Journal of cellular physiology.
[56] J. Birch,et al. Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. , 2009, Neuro-oncology.
[57] T. Shaikh,et al. Duplication of 7q34 in Pediatric Low‐Grade Astrocytomas Detected by High‐Density Single‐Nucleotide Polymorphism‐Based Genotype Arrays Results in a Novel BRAF Fusion Gene , 2009, Brain pathology.
[58] David T. W. Jones,et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.
[59] A. Gajjar,et al. Chemotherapy for Malignant Brain Tumors of Childhood , 2008, Journal of child neurology.
[60] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[61] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[62] G. Reifenberger,et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. , 2008, The Journal of clinical investigation.
[63] D. Peeper,et al. BRAFE600 in benign and malignant human tumours , 2008, Oncogene.
[64] L. Chin,et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.
[65] Chunxu Qu,et al. EWS/FLI-1 Induces Rapid Onset of Myeloid/Erythroid Leukemia in Mice , 2007, Molecular and Cellular Biology.
[66] B. Scheithauer,et al. The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.
[67] P. Liberski,et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] A. Hoischen,et al. Frequent loss of chromosome 9, homozygous CDKN2A/p14ARF/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas , 2007, Oncogene.
[69] D. Ellison,et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] Gary L Gallia,et al. PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme , 2006, Molecular Cancer Research.
[71] D. Evans,et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] J. Shay,et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.
[73] A. Levine,et al. The p53 pathway: positive and negative feedback loops , 2005, Oncogene.
[74] Y. Xiong,et al. Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues , 2005, Oncogene.
[75] Mathew J Garnett,et al. Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.
[76] A. Gajjar,et al. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. , 2004, The oncologist.
[77] K. Fukunaga,et al. Neurofibromatosis Type I Tumor Suppressor Neurofibromin Regulates Neuronal Differentiation via Its GTPase-activating Protein Function toward Ras* , 2003, Journal of Biological Chemistry.
[78] F. Sommerer,et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.
[79] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[80] I. Pollack,et al. Expression of p53 and prognosis in children with malignant gliomas. , 2002, The New England journal of medicine.
[81] I. Pollack,et al. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. , 2001, Cancer research.
[82] P. Steinbok. Recurrence Patterns and Anaplastic Change in a Long-Term Study of Pilocytic Astrocytomas , 1998, Pediatric Neurosurgery.
[83] J. Langston,et al. Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] J. McComb,et al. Recurrence patterns and anaplastic change in a long-term study of pilocytic astrocytomas. , 1997, Pediatric neurosurgery.
[85] J. Barnholtz-Sloan,et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.
[86] R. Barbella-Aponte,et al. [Pleomorphic xanthoastrocytoma with intraventricular extension and anaplastic transformation in an adult patient: Case report]. , 2012, Neurocirugia.
[87] Barbara S. Paugh,et al. Targeted Therapy for Braf V600e Malignant Astrocytoma Statement of Translational Relevance , 2022 .
[88] J. Adolfsson,et al. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[89] D. Miller,et al. Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas. , 2000, Human pathology.
[90] P. Kleihues,et al. Primary and secondary glioblastomas: from concept to clinical diagnosis. , 1999, Neuro-oncology.
[91] J. Drake,et al. Development of anaplastic changes in low-grade astrocytomas of childhood. , 1994, Neurosurgery.
[92] R. Barnard,et al. The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.